Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Christopher Flint Obrien sold 8,734 shares of Neurocrine Biosciences stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $50.00, for a total transaction of $436,700.00. Following the completion of the sale, the insider now owns 57,707 shares in the company, valued at approximately $2,885,350. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) opened at 52.15 on Friday. The company’s market capitalization is $4.60 billion. Neurocrine Biosciences, Inc. has a 52 week low of $37.35 and a 52 week high of $55.38. The company’s 50 day moving average price is $49.49 and its 200-day moving average price is $47.26.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Thursday, August 3rd. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.01. The company had revenue of $6.34 million during the quarter, compared to analysts’ expectations of $0.61 million. During the same quarter last year, the business posted ($0.46) earnings per share. Equities research analysts expect that Neurocrine Biosciences, Inc. will post ($2.45) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This report was first published by BNB Daily and is the property of of BNB Daily. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.baseball-news-blog.com/2017/08/19/neurocrine-biosciences-inc-nbix-insider-christopher-flint-obrien-sells-8734-shares-of-stock-updated-updated.html.
Several brokerages have commented on NBIX. Cowen and Company reissued an “outperform” rating and set a $65.00 price objective (up previously from $60.00) on shares of Neurocrine Biosciences in a research report on Wednesday, August 9th. Piper Jaffray Companies set a $68.00 price objective on Neurocrine Biosciences and gave the company a “buy” rating in a research report on Wednesday, May 24th. BidaskClub raised Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. BMO Capital Markets lifted their price target on Neurocrine Biosciences from $75.00 to $84.00 and gave the stock an “outperform” rating in a research report on Friday, August 4th. Finally, Oppenheimer Holdings, Inc. set a $70.00 price target on Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Wednesday, May 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seventeen have assigned a buy rating to the company’s stock. Neurocrine Biosciences has an average rating of “Buy” and an average target price of $68.25.
A number of hedge funds have recently bought and sold shares of NBIX. FMR LLC raised its stake in Neurocrine Biosciences by 9.8% in the second quarter. FMR LLC now owns 13,211,023 shares of the company’s stock valued at $607,707,000 after buying an additional 1,180,874 shares during the period. Vanguard Group Inc. raised its stake in Neurocrine Biosciences by 2.8% in the second quarter. Vanguard Group Inc. now owns 6,922,294 shares of the company’s stock valued at $318,426,000 after buying an additional 186,329 shares during the period. Janus Henderson Group PLC bought a new stake in Neurocrine Biosciences during the second quarter valued at approximately $246,888,000. BlackRock Inc. raised its stake in Neurocrine Biosciences by 14,216.0% in the first quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock valued at $217,884,000 after buying an additional 4,996,784 shares during the period. Finally, Janus Capital Management LLC raised its stake in Neurocrine Biosciences by 85.0% in the first quarter. Janus Capital Management LLC now owns 4,359,384 shares of the company’s stock valued at $188,759,000 after buying an additional 2,002,899 shares during the period. 95.87% of the stock is currently owned by hedge funds and other institutional investors.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.